Fingolimod 0.5mg Capsules

Fingolimod 0.5 mg Capsules – Generic Gilenya

Fingolimod 0.5 mg Capsules are a generic form of Gilenya, containing fingolimod as the active ingredient. Fingolimod is an oral disease-modifying medicine used for eligible patients with relapsing forms of multiple sclerosis (MS), a chronic neurological condition involving immune-mediated damage to the central nervous system.

Fingolimod belongs to the sphingosine-1-phosphate (S1P) receptor modulator class. It changes the movement of certain lymphocytes, a type of white blood cell involved in immune responses. By reducing the circulation of selected lymphocytes and limiting their movement into the central nervous system, fingolimod can help reduce inflammatory disease activity associated with multiple sclerosis.

The 0.5 mg capsule is a commonly used adult strength. The appropriate product, dosage and treatment plan depend on the patient's clinical circumstances and the approved prescribing information in the relevant country.

Product Information

Important Assessments Before Treatment

Before fingolimod treatment begins, the prescribing team evaluates relevant medical history and baseline test results. Depending on the local product label and individual circumstances, assessments may include:

• Cardiac assessment: Heart rate, cardiac history, electrocardiogram findings and medicines that can affect heart rate or cardiac conduction.
• Blood count: A recent complete blood count, given fingolimod's effects on circulating lymphocytes.
• Liver tests: Liver enzymes and bilirubin.
• Infection assessment: Relevant infection history and immune status.
• Eye examination: Assessment for macular oedema risk and appropriate follow-up.
• Vaccination status: Immunisation history, including varicella immunity where relevant.
• Pregnancy considerations: Pregnancy status, contraception and reproductive plans where applicable.

Monitoring during treatment depends on the current product information and the patient's clinical circumstances.

Generic Gilenya vs. Brand Gilenya

Gilenya is the reference brand containing fingolimod. Generic fingolimod capsules contain the same active ingredient and strength as the corresponding reference product when authorised as a generic equivalent.

The generic product may differ from the reference brand in manufacturer, capsule appearance, packaging and inactive ingredients. The supplied product's label identifies the specific manufacturer, formulation, pack size and market authorisation.

Fingolimod Compared With Other Multiple Sclerosis Medicines

Fingolimod is one of several disease-modifying therapies used for multiple sclerosis. Other medicines include dimethyl fumarate, teriflunomide, siponimod, ozanimod and other therapies with different mechanisms, indications and monitoring requirements.

These medicines are not interchangeable on a milligram-for-milligram basis. Selection depends on the type and activity of MS, previous treatment, medical history, safety considerations, pregnancy plans and local approvals.

How it works

Fingolimod is converted in the body to fingolimod phosphate, its active form. This active form interacts with specific sphingosine-1-phosphate receptors involved in lymphocyte movement.

The medicine alters lymphocyte trafficking, retaining certain lymphocytes in lymphoid tissues and reducing the number circulating in the blood. This limits the movement of selected immune cells into the central nervous system, where they can contribute to inflammatory damage associated with multiple sclerosis.

By modifying this immune-cell movement, fingolimod can reduce MS disease activity in appropriate patients. It is a disease-modifying treatment rather than a cure, and it does not reverse all existing neurological damage.

Fingolimod is used to treat eligible patients with relapsing forms of multiple sclerosis. The precise approved indication and minimum age depend on the national authorisation and product label.

1. Relapsing-Remitting Multiple Sclerosis

Relapsing-remitting multiple sclerosis (RRMS) involves episodes of new or worsening neurological symptoms, known as relapses, followed by periods of partial or complete recovery. Fingolimod is a disease-modifying therapy used to reduce disease activity in eligible patients with this condition.

2. Active Secondary Progressive Multiple Sclerosis

Secondary progressive multiple sclerosis (SPMS) can develop after an initial relapsing course. In active SPMS, relapses or other evidence of inflammatory disease activity may continue while disability progresses. Fingolimod may be indicated for certain patients under specific national product labels.

3. Clinically Isolated Syndrome

Clinically isolated syndrome (CIS) refers to a first clinical episode suggestive of inflammatory demyelination in the central nervous system. It is included within the US-labelled relapsing-MS indication for fingolimod. Whether it is an approved use in another country depends on that country's product information.

The appropriate fingolimod dose depends on age, body weight, the approved local regimen and the prescribing clinician's assessment.

For the US-labelled regimen, adults and eligible paediatric patients aged 10 years and older who weigh more than 40 kg generally receive 0.5 mg orally once daily. The US label specifies a different dose for certain paediatric patients weighing 40 kg or less, so the 0.5 mg strength is not suitable for every patient.

Fingolimod may be taken with or without food, following the product-specific instructions.

First-Dose Monitoring

Fingolimod may slow the heart rate and affect cardiac conduction after the first dose. Treatment initiation requires a structured monitoring procedure in an appropriate healthcare setting. Under the US label, this includes observation for at least six hours, pulse and blood pressure checks, and electrocardiograms before dosing and at the end of the observation period. Some patients require extended or overnight monitoring.

Restarting Treatment After an Interruption

Restarting fingolimod after an interruption can require first-dose cardiac monitoring again. The monitoring requirement depends on how long treatment was interrupted, the point in treatment when the interruption occurred and the applicable product label.

Fingolimod may cause side effects, and their severity varies among patients. Reported effects include:

• Headache
• Cough
• Diarrhoea
• Back pain
• Elevated liver enzymes
• Increased susceptibility to infections
• Slowing of the heart rate, especially after the first dose
• Blood pressure changes
• Macular oedema
• Skin changes, including an increased risk of certain skin cancers
• Rare but serious neurological infections or complications

Significant visual changes, signs of serious infection, fainting, breathing difficulties or new neurological symptoms require prompt medical assessment.

Heart Rate and Cardiac Conduction

Fingolimod can cause bradycardia and atrioventricular conduction abnormalities, especially after the first dose or following certain treatment interruptions. Cardiac screening and supervised first-dose monitoring are important elements of treatment.

Infection Risk

Fingolimod changes immune-cell circulation and can increase susceptibility to infections. Assessment for active infection and review of blood counts are important before treatment. Infection monitoring may remain relevant after discontinuation, as described in the applicable product label.

Liver Effects

Elevated liver enzymes and clinically significant liver injury have been reported. Liver function should be assessed before treatment and monitored during therapy as indicated.

Eye Health

Macular oedema has been associated with fingolimod. Eye examinations before treatment and during follow-up may be required, particularly for patients with diabetes or a history of uveitis.

Pregnancy

Fingolimod may cause fetal harm. Pregnancy risks, contraception and treatment planning should be reviewed with the prescribing clinician where relevant. Discontinuation requires clinical planning because MS disease activity may increase after stopping treatment.

Discontinuation and Disease Activity

Severe worsening of multiple sclerosis has been reported after fingolimod is discontinued. Stopping treatment or transitioning to another disease-modifying therapy requires an appropriate clinical plan and follow-up.

Contraindications and Drug Interactions

Fingolimod is not appropriate for everyone. Under the US prescribing information, contraindications include certain recent major cardiovascular events, specific serious cardiac conduction disorders without a functioning pacemaker, a baseline QTc interval of 500 milliseconds or greater, certain arrhythmias requiring class Ia or class III antiarrhythmic treatment, and hypersensitivity to fingolimod or its ingredients.

Potential interactions include medicines that slow heart rate or atrioventricular conduction, drugs associated with QT prolongation, and treatments that suppress the immune system or alter immune responses. Live attenuated vaccines also require special consideration during and after treatment.

The exact contraindications and interactions should be checked against the current local product information and the patient's medication list.